Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer

BACKGROUND: To analyze the efficacy and safety of everolimus 5 mg/day in combination with endocrine drugs in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer using real-world clinical data. METHODS: Clinical data of hormone...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hui-Qiang, Zhou, Jin-Mei, Zhang, Shao-Hua, Bian, Li, Xiao, Jin-Yi, Hao, Xiao-Peng, Jiang, Ze-Fei, Wang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573446/
https://www.ncbi.nlm.nih.gov/pubmed/34805355
http://dx.doi.org/10.21037/atm-21-4273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573446/
https://www.ncbi.nlm.nih.gov/pubmed/34805355
http://dx.doi.org/10.21037/atm-21-4273

Ejemplares similares